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Background: Diabetes mellitus is a group of metabolic diseases characterized by high blood sugar (glucose) levels
that result from defects in insulin secretion, or action, or both. Inspired by previous report the release of ATP from
RBCs, which may participate in vessel dilation by stimulating NO production in the endothelium through purinergic
receptor signaling and so, the aim of this study is to clearly determined relationship between RBC ATP/ADP ratio
with nitric oxide.
Methods: The ATP/ADP ratio of erythrocytes among four groups of normal individuals (young & middle age),
athletes’ subjects and diabetic patients were compared and the relationship between ATP/ADP ratio and NO level
of plasma was determined with AVOVA test and bioluminescence method.
Results: ATP/ADP level in four groups normal (young & middle age), athletes, diabetes] are measured and analyzed
with ANOVA test that show a significant difference between groups (P-value < 0.001). A significant positive
correlation was found between RBC ATP/ADP content (r = 0.705; P < 0.001). Plasma NO content is also analyzed
with ANOVA test which shows a significant difference between groups.
Conclusion: In this study, a positive relationship between RBC ATP/ADP ratio and NO was found. Based on the
obtained result, higher RBC ATP/ADP content may control the ratio of plasma NO in different individuals, also this
results show that ATP can activate endothelial cells in NO production and is a main factor in releasing of NO from
endothelial cells.
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Diabetes mellitus is a group of metabolic diseases which
interfere with energy homeostasis [1]. Diabetes is one of the
most costly chronic diseases with an estimated worldwide
prevalence of 170 million in 2002, which is expected to
double by 2030 according to the World Health Organization
[2]. The most common macrovascular complication of
diabetes is atherosclerosis, which increases the risk for
myocardial infarction, stroke, and peripheral artery dis-
ease, the latter being the leading cause of limb amputation
in civilized countries. Microvascular complications consist
of retinopathy and nephropathy, the leading causes of
blindness and renal failure [3]. There is now substantial
evidence indicating that endothelial dysfunction, charac-
terized by diminished endothelium dependent relaxation,* Correspondence: mrmohajeri@tums.ac.ir
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reproduction in any medium, provided the oris abnormal in experimental models of diabetes [4-8].
Several other studies have also demonstrated impaired
endothelium dependent vasodilation in human diabetic
patients [9,10]. There is substantial evidence suggesting
that high concentrations of glucose could reduce NO
availability due to an increase in superoxide anion produc-
tion [11]. Further, elevated glucose levels may lead to a de-
crease in cellular concentrations of nicotinamide adenine
dinucleotide phosphate (reduced form) (NADPH) through
activation of the polyol pathway [12]. As NADPH is an
essential cofactor of NO synthase (NOS) for NO synthesis,
its depletion could lead to a reduction in endothelial NO
production. NO mediates the endothelium-dependent
vasodilation in response to stimuli such as shear stress,
insulin, and acetylcholine [13]. Recent evidence suggests
that NO interacts with other flow-induced vasodilation
mediators, including prostacyclin and adenosine, and this
interaction results in net hemodynamic changes. NO hasl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[14]. As a potent endogenous vasodilator, NO has numer-
ous beneficial effects that preserve normal vascular func-
tion. For example, NO activates guanylate cyclase in
vascular smooth muscle, and increases the production of
cyclic guanosine monophosphate (cGMP). cGMP, as a sec-
ond messenger, mediates many of the biological effects of
NO, e.g. causing relaxation of smooth muscle and inhibit-
ing platelet aggregation [15]. In addition, NO inhibits
platelet activation and adhesion to the surface of endothe-
lium. NO reduces vascular oxidative stress and inhibits
superoxide generation [16,17]. In addition, NO stimulates
angiogenesis, which plays an important role in wound
healing, vascular remodeling, and conditions like myocar-
dial infarction and diabetic retinopathy [18]. NO is also a
mediator of the immune response, a neurotransmitter, a
cytotoxic free radical and a widespread signaling molecule
[16,18]. NO stimulates insulin release from pancreatic ß
cells in the presence of glucose [19]. These properties sug-
gest that the level of NO production by the endothelium
may play a pivotal role in the regulation of vascular dis-
ease. Therefore, impaired endothelial NO production may
constitute a critical manifestation of proatherogenic events
in the vascular wall, including increased vascular tone,
platelet aggregation, endothelial barrier dysfunction, vas-
cular inflammation, and smooth muscle cell proliferation.
Nisoli et al [20] recently reported that the NO-cGMP-
dependent pathway controls mitochondrial biogenesis and
body energy balance. For example, NOS null mutant mice
had a reduced metabolic rate and accelerated weight gain
[20], insulin resistance [21], hypertension, and hyperlipid-
emia [22]. Accordingly, it was reported that the red blood
cell (RBC) is a determinant of endogenous nitric oxide
(NO) synthesis in the pulmonary circulation; i.e., in the
isolated perfused rabbit lung, RBCs obtained from either
rabbits or healthy humans were required component of
the perfusate in order to demonstrate flow-induced en-
dogenous NO synthesis [23]. RBCs contain concentrations
of ATP adequate to activate the endothelial P2y purinergic
receptors, resulting, thereby, in synthesis of NO [24,25].
Importantly, the component of blood, responsible for
the stimulation of endogenous NO synthesis, was deter-
mined to be the RBC, via the release of adenosine tri-
phosphate (ATP) [26]. Indeed, the application of ATP to
endothelial cells resulted in an increase in NO synthesis
[24,27]. ATP is of particular interest because it is
present in millimolar amounts in RBCs [28]. In the
present study, we investigated the RBC ATP/ADP ratio
and plasma nitric oxide in different groups (normals,
diabetes). We characterized a significant coherency be-
tween ATP/ADP and nitric oxide .in addition, in this
study we determined these factors in athletics’ subject,
all of them were jodo national team. Finally, to bold the
results, they comparison with each other.Materials and methods
In this study we investigated on human subjects, all con-
trol subjects were healthy volunteer living in the commu-
nity, and none was acutely ill. None exhibited evidence of
cardiac or chronic kidney disease and all were euthyroid
with normal liver function tests and normal value for
plasma urea, creatinine and electrolytes. Furthermore,
healthy subjects were drug free and with a negative family
history of diabetes mellitus or hypertension. The subjects
were fully informed of any risks and discomforts asso-
ciated with the experiments before giving their informed
written consent to participate. The studies conformed to
the code of Ethics of the World Medical Association
(Declaration of Helsinki) and were approved by the Ethics
Committee of Shariati Hospital, Tehran University of Med-
ical Science of Iran. RBC of 40 uncontrolled diabetes
patients was collected (40-65 years) and at the time of the
study (HbA1C% 8.79±0.19) we also collected RBC from
60 healthy volunteer (23-55 years), this group was divided
into three classes, normals [young individuals ( 20-33 years)
and middle age subjects ( 40-55 years)] and athletes (20-
33 years). The following parameters were determined in all
blood samples which collected at early morning after over-
night fast: erythrocyte ATP, ADP content and plasma nitric
oxide (NO) level.ATP assay method in RBC
ATP was measured by luciferin-luciferase technique
[29,30]. In which the amount of light generated by the re-
action of ATP with recombinant luciferase is dependent
on the ATP concentration. Sensitivity was augmented by
addition of the D-luciferin to the luciferase. A, 50 μl sam-
ple of RBC, lysed with TCA 10% (tricoloroaceticacid) and
neutralized with KOH 1 M and diluted with hepes buffer
100 mM pH 7.8 (1:64), injected into a cuvette containing
10 μl luciferin (sigma), 10 μl Mgso4, 10 μl luciferase
(1 mg/ml). The peak light efflux from cuvette to which ei-
ther known ATP standards or samples are added was deter-
mined using a luminometer (Sirius tube Luminometer,
Berthold Detection System, Germany), a ATP standard
curve was obtained on the day of each experiment.RBC ADP assay procedure
ADP was measured by the coupled assay of pyruvate
kinase with luciferin-luciferase technique [31], in which
at first we injected 5 μl pyruvate kinase (1 mg/ml) into a
cuvettes containing 50 μl RBC (lysed, neutralized and
diluted), 5 μl PEP (phospho enol pyruvate 20 mM,
sigma), 5 μl KCl and patience for 7 min since the ADPs
existed in the sample converted to ATP, then added
10 μl luciferin (10 mM), 10 μl luciferase (1 mg/ml) and
10 μl Mgso4. The peak light efflux from cuvette to which
either known ADP standards or samples are added was
Table 1 Age and sex characteristics of studied subjects:
Erythrocyte ATP/ADP and plasma NO content, Tamhan
test for ATP/ADP group comparison, as shown in this
table the difference between groups are significant
(P-value <0.001)
Normal(Y)* Normal(M)** Athletes Diabetes
N 20 20 20 20
Age(year) 26.7 ± 0.49 50 ± 0.60 27.7 ± 0.61 60 ± 1.7
Sex Male Male Male Male
BMIa 25 28 20 33
ATP/ADPb 3.08 ± 0.09 2.4 ± 0.07 4.96 ± 0.411 1.26 ± 0.08
NO(ng/dl)c 38.27 ± 1.4 31 ± 1.65 50.58 ± 1.33 25.37 ± 0.96
HbA1C% 4.86 ± 0.13 5.31 ± 0.11 4.09 ± 0.08 8.79 ± 0.19
FBSd 84.05 ± 2.5 102.5 ± 2.7 76 ± 0.94 172± 5.9
a = Body Mass Index [weight/(height)2] = kg/m2, b = P value < 0.001 c = P
value < 0.001 d = fasting blood sugar * Y = young, ** M = middle age
Scheffe test for comparison between groups shows that NO differences
between normal(M) and diabetes individuals are not significant.
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curve was obtained on the day of each experiment.
NO assay procedure
NO was measured by the dye assay based on Griess re-
action [32]. In this study to inhibition of blurred solution
which interferes with assay we used Znso4 as a protein
degenerative (solution clarification) [33,34]. In this assay
which act based on Griess reaction, added 100 μl a mix-
ture of solution, NEDD (N-1-naphtylethylenediamine)
and sulphanomide (1:1) to 100 μl of clarified serum, to
doing reaction and dye forming, solution mixture placed
into incubator 37°C for 30 min. after this time dye
formed from this reaction measured at 540 nm by Elisa
reader ( Sunrisa, Tecan, Austrian).
Statistical method
Statistical significance among experimental periods and
groups was determined with analysis of variance, Tamhane
test and Scheffe test for multiple comparisons, Bivariate
correlation for relation between variables and regression for
prediction. A P-value 0.05 or less was considered statisti-
cally significant. Results are reported as the means±SEM.
Results
Human subject studied
RBCs are taken from 40 male diabetic patients who were
diagnosed according by American Diabetes Association
Guideline 2011 [35]. The average age of the patients was
60.5±1.7 years. Baseline characteristic data are summarizedFigure 1 The comparison of ATP/ADP level among 4 groups (diabetein Table 1. In addition, RBC of 60 healthy human volun-
teers [20 athletes, 40 Normals (20 youngs, 20 middle age)]
with equal sex for all was sampled. Average ages for
athletic individuals without medication and history of
diabetes disease, was 27.7± 0.61 and for normal control
was 26.7± 0.49 and 50± 0.60.
ATP/ADP level between groups
In this study the control individuals divided to three
groups, normal (young) & normal (middle age) and athletes, Normal (Y = young, M = middle age) and athletes.
Figure 2 The comparison of NO level among 4 groups (diabetes, Normal (Y = young, M = middle age) and athletes.
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Normal (M), athletes, Diabetes) was measured and ana-
lyzed with ANOVA test, the result showed a significant
difference between groups (P value < 0.001), the result are
summarized in Table 1 and Figure 1.NO level between groups
In this study we measured NO by dye assay and result was
analyzed with ANOVA test. As the difference variance be-
tween groups was not significant, data were analyzed with
fisher and Scheffe test. The results are summarized in
Table 1 and Figure 2.Figure 3 Correlation between NO and RBC ATP/ADP with bar curve.Correlation between RBC ATP/ADP content and NO
A significant positive correlation was found between
RBC ATP/ADP content (r = 0.705; P < 0.001). In this
study, a positive relationship between ATP/ADP and NO
is found, accordingly; 0.705 unit increase in NO is ac-
companied by 1 unit increase of ATP/ADP ratio. There-
fore, based on experimental measurements reported here,
using B Coefficient a formula for prediction of ATP/ADP
ratio could be obtained : ATP/ADP = -0.990+ 0.105 [NO].
Discussion
Nitric oxide (NO) is an omnipresent intercellular messen-
ger in all vertebrates, modulating blood flow, thrombosis,
Table 2 Pearson correlation between ATP/ADP and NO,
this table showed that if NO 0.705 increased ATP/ADP
level 1 unit increased
ATP/ADP& NO Sig.
Pearson correlation 0.705* 0.000
Regression 0.705 0.000
*. Correlation is significant at the 0.01 level (2-tailed).
Relationship between ATP/ADP and NO (Regression).
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1996 had reported the erythrocyte, via its ability to release
ATP, has been identified as a potential regulator of vascu-
lar resistance once released from the erythrocyte into the
circulation, ATP can activate purinergic receptors, specif-
ically those of the P2y subfamily, present on the vascular
endothelium, resulting in the synthesis and release of NO.
NO released abluminally interacts with vascular smooth
muscle, resulting in its relaxation [36,37]. Controversially,
Jaffrey J. etales have reported that inhibitory action of NO
on ATP release from erythrocytes is the result of inactiva-
tion of one or more components of signal transduction
pathway which contribute in ATP releasing in RBC. In this
study we measured RBC ATP/ADP content and plasma
NO between four groups (Normal (young) & (middle age),
athletes, diabetes) (Figures 1, 2 Table 1). The present study
investigate the relationship between of RBC ATP/ADP
content and plasma NO level and the effect of exercise on
RBC ATP/ADP content and plasma NO production. A
positive significant correlation (Figure 3, Table 2) between
plasma NO and ATP/ADP content of RBC among four
groups has been observed. This observation suggests
higher metabolic rate (ATP/ADP ratio) in athletes in com-
parison with normal and type2 diabetes. Other study
reported that athletes have high ATP/ADP content in com-
parison with normal subject [38]. No correlation between
RBC ATP/ADP content and plasma NO level has ever
been reported. It is a sight of thought that plasma NO is a
signal for inhibition of platelete aggregation and also is a
signal for velocity in blood flowing which lead to woundFigure 4 Proposed scheme for the potential mechanism of factors wh
myocardium leading to improvements in eNOS function.healing. Previous works show that exposure of endothelial
cells to oxidants leads to cellular energetic crisis, which is
prevented by Poly (ADP ribose) polymerase (PARP) inhib-
ition [39] this event simultaneously led to oxidative and
peroxidative injury, decrease in NAD+, NADPH which
make decrease in ATP production and eNOS activity
which led to endothelial dysfunction (Figure 4). Sprague
et al. (1996) reported that both rabbit and human erythro-
cytes release ATP in response to mechanical deformation
produced by passage of erythrocytes through filters with an
average pore size of 5 μm. Indeed, it has been reported that
the RBCs from people with type 2 diabetes are less deform-
able than those RBCs obtained from healthy controls
[40-42]. Have any role nitric oxide in cell metabolic rate?
There is now clear evidence for a role of nitric oxide (NO)
in mitochondrial biogenesis. NO donors increase the
protein and mRNA expression of peroxisome proliferator-
activated receptor coactivator 1 (PGC-1), nuclear respira-
tory factor 1 (NRF-1), and mitochondrial transcription
factor A (mtTFA) in muscle cells and adipocytes of rodents
[43], which are involved in coordinating mitochondrialich contribute in endothelial dysfunctionin the diabetic
Figure 5 Exercise induced alterations in the diabetic myocardium leading to improvements in eNOS function. Decrease in level or
inhibition of function, Increase in level or improvement of function. Improvements derived from increased insulin sensitivity are from the findings
of Zhang et al. [46].
Bakhtiari et al. Journal of Diabetes & Metabolic Disorders 2012, 11:9 Page 6 of 7
http://www.jdmdonline.com/content/11/1/9biogenesis [44,45]. This process is dependent on the down-
stream messenger of NO, cGMP, via the activation of sol-
uble guanylate cyclase (sGC) [43]. Furthermore, blocking
the activation of sGC also blocks mitochondrial biogenesis
induced by NO donors [43]. As mentioned above in ath-
letes the ATP/ADP ratio and NO have a more positive sig-
nificant in comparison with others, this due to exercise led
to increase in ca+2 and then activation of nitric oxide syn-
thase from a series of signal such as increase in ATP/ADP
ratio, NADPH ,. . . and also decrease in reactive oxygen spe-
cies(ROS) [46] (Figure 5).
In conclusion, according to the result obtained in this
investigation; the relationship between RBC ATP/ADP
ratio and plasma NO is a positive significant and have a
reciprocal correlation these factors was high in athletes
and normal individuals in comparison with diabetic
patients. It seems that ATP/ADP content may be consid-
ered as a main stimulator for NO secretion from endo-
thelial cells, diabetes control and diabetic consequence
such as stroke.Competing interest
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